Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the ...

Bio-Rad Laboratories BIO is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -6.31% in ...

Zooming in on the latest balance sheet data, we can see that Bio-Rad Laboratories had liabilities of US$613.7m due within 12 months and liabilities of US$3.15b due beyond that. Offsetting these ...

Bio-Rad Laboratories recently launched three new StarBright dyes for flow cytometry. The dyes help researchers to achieve consistent and reproducible staining. The company recently reported increased ...

The Securities and Exchange Commission has charged Bio-Rad Laboratories, a clinical diagnostic and life science research company based in California, with violating the Foreign Corrupt Practices Act ...

Ronald W. Hutton - Bio-Rad Laboratories, Inc. Christine A. Tsingos - Bio-Rad Laboratories, Inc. Norman D. Schwartz - Bio-Rad Laboratories, Inc. Annette Tumolo - Bio-Rad Laboratories, Inc. John Goetz - ...

Bio-Rad Laboratories (NYSE: BIO) reported earnings on May 7. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on ...